Numerous healthcare technology companies are jostling to get products leveraging AI in front of healthcare providers on the front lines of the battle against COVID-19.
The White House is working with IBM and the U.S. Department of Energy to launch a sprawling public-private consortium aimed at rapidly “unleashing the full capacity of America’s world-class supercomputers” to fight COVID-19.
Amazon Web Services is corralling the expertise of more than 30 research institutions, businesses and startups to help combat COVID-19. The cloud giant has allotted $20 million for the work.
The idea is to initially place the device in medical waiting areas, from where it would help prepare staff for caseload ebbs and flows. Later it might be set in larger public spaces, helping to monitor epidemiological trends at the population level.
Mayo Clinic researchers have found that primary care providers welcome the concept of AI-based clinical decision support (CDS) while preferring not to use the technology—at least as configured for their tryout adoption—in day-to-day practice.
Tampa General Hospital in Florida has admitted three patients with COVID-19. Halfway around the world, Sheba Medical Center in Israel has seen 40. Both expect exponential increases—and both are using new AI applications to respond.
Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus.
